U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 4 of 4 results

Status:
US Approved Rx (2019)
First approved in 2017

Class (Stereo):
CHEMICAL (ABSOLUTE)



Netarsudil ophthalmic solution (Rhopressa) is a Rho kinase inhibitor for the treatment of open-angle glaucoma or ocular hypertension. As of December 18, 2017 the FDA approved Aerie Pharmaceutical's Rhopressa (netarsudil ophthalmic solution) 0.02% for...
Status:
US Approved Rx (2019)
First approved in 2017

Class (Stereo):
CHEMICAL (ABSOLUTE)



Netarsudil ophthalmic solution (Rhopressa) is a Rho kinase inhibitor for the treatment of open-angle glaucoma or ocular hypertension. As of December 18, 2017 the FDA approved Aerie Pharmaceutical's Rhopressa (netarsudil ophthalmic solution) 0.02% for...
Status:
US Approved Rx (2019)
First approved in 2017

Class (Stereo):
CHEMICAL (ABSOLUTE)



Netarsudil ophthalmic solution (Rhopressa) is a Rho kinase inhibitor for the treatment of open-angle glaucoma or ocular hypertension. As of December 18, 2017 the FDA approved Aerie Pharmaceutical's Rhopressa (netarsudil ophthalmic solution) 0.02% for...
Status:
US Approved Rx (2019)
First approved in 2017

Class (Stereo):
CHEMICAL (ABSOLUTE)



Netarsudil ophthalmic solution (Rhopressa) is a Rho kinase inhibitor for the treatment of open-angle glaucoma or ocular hypertension. As of December 18, 2017 the FDA approved Aerie Pharmaceutical's Rhopressa (netarsudil ophthalmic solution) 0.02% for...